Voyager Therapeutics, Inc.
VYGR
$3.36
$0.010.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -70.38% | -43.75% | -68.00% | 3.40% | -26.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -70.38% | -43.75% | -68.00% | 3.40% | -26.22% |
| Cost of Revenue | 13.77% | 25.65% | 32.46% | 42.08% | 48.66% |
| Gross Profit | -351.69% | -424.66% | -126.67% | -37.05% | -72.51% |
| SG&A Expenses | 0.10% | 4.38% | 0.27% | 9.18% | 12.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.33% | 20.12% | 23.45% | 32.35% | 37.56% |
| Operating Income | -2,805.13% | -466.01% | -163.94% | -73.32% | -104.75% |
| Income Before Tax | -1,205.04% | -3,511.56% | -148.11% | -49.38% | -89.95% |
| Income Tax Expenses | -0.59% | -4.18% | -52.77% | 50.00% | -12.32% |
| Earnings from Continuing Operations | -1,296.21% | -2,682.29% | -149.12% | -50.52% | -90.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,296.21% | -2,682.29% | -149.12% | -50.52% | -90.58% |
| EBIT | -2,805.13% | -466.01% | -163.94% | -73.32% | -104.75% |
| EBITDA | -16,356.84% | -636.31% | -157.95% | -64.86% | -99.22% |
| EPS Basic | -683.06% | -8,479.41% | -134.79% | -43.86% | -86.70% |
| Normalized Basic EPS | -576.48% | -169,340.00% | -131.29% | -39.83% | -83.91% |
| EPS Diluted | -756.10% | -3,033.05% | -136.79% | -41.55% | -87.47% |
| Normalized Diluted EPS | -620.06% | -4,094.06% | -132.73% | -36.98% | -84.45% |
| Average Basic Shares Outstanding | 14.88% | 23.03% | 34.11% | 30.08% | 25.73% |
| Average Diluted Shares Outstanding | 14.26% | 22.32% | 32.09% | 29.55% | 24.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |